BHWM
TEVA icon

Beaird Harris Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Beaird Harris Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324 Hold
10
– – ﹤0.01% 629
2026
Q1 		$288 Hold
10
– – ﹤0.01% 607
2025
Q4 		$298 Sell
10
-60
-86% -$1.48K ﹤0.01% 626
2025
Q3 		$1.41K Buy
+70
New +$1.23K ﹤0.01% 544

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Beaird Harris Wealth Management's TEVA Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 10 shares worth $324. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Beaird Harris Wealth Management first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.41K in Q3 2025. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Beaird Harris Wealth Management held 10 shares of Teva Pharmaceuticals worth $324 as of Q2 2026.
  • Beaird Harris Wealth Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #629 holding.
  • Beaird Harris Wealth Management first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Beaird Harris Wealth Management's Teva Pharmaceuticals position peaked at $1.41K in Q3 2025.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.